COMP <GO>
LFST vs MRK // GROSS PROFIT MARGIN
LifeStance Health Group Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: LFST 3
— MRK 8
■ METRIC PARITY
LAST: $13.64 (+1.83%) • MKT CAP: $5.21B
gross-margins
—
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFST VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFST | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.20% | 20.70% | -19.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.3x | 15.3x | +80.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 3.42% | -1.31 | MRK | /fcf-yield <GO> |
| Operating Margin | 1.70% | 34.30% | -32.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.70% | 28.10% | -27.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 13.90% | 1.30% | +12.60 | LFST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 5.19 | -0.35 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LFST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.8 | 51.7 | +13.06 | LFST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.21B | $361.02B | -$355.81B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFST REV | MRK REV | LFST GROSS % | MRK GROSS % | LFST FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.42B | $65.01B | — | 74.8% | $110.0M | $12.36B |
| FY 2024 | $1.25B | $64.17B | — | 76.3% | $85.7M | $18.10B |
| FY 2023 | $1.06B | $60.12B | — | — | -$16.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFST // BETA —
MRK // BETA 0.92